Novostia, a leading medical technology company advancing a groundbreaking heart valve replacement, has announced a leadership change and secured CHF 5.6 million in funding. Soad El Ghazouani has been appointed as the new CEO, taking over from Alain Barbal, who will now join the Board of Directors. The new funds will accelerate the company’s development and enhance its clinical evidence base.
Appointment of New General Manager
Novostia is excited to announce the appointment of Soad El Ghazouani as the new General Manager. With over 25 years of international experience in developing and commercializing disruptive innovations in the cardiovascular field, Soad brings a wealth of expertise. She recently co-founded and served as CEO of T-Heart and has held senior roles in various medical technology companies, from start-ups to multinationals. Soad holds an MBA in International Business and a degree in Biomedical Engineering.
“I am honored to join Novostia at this crucial juncture,” said Soad. “The TRIFLO heart valve has shown tremendous potential to transform patient care, and I am excited to lead our talented team as we continue to innovate and deliver exceptional value to all stakeholders.”
Successful Fundraising to Accelerate Development
Novostia has also secured CHF 5.6 million in new funding to advance its clinical phase and prepare for the Series B round. This investment highlights strong confidence in Novostia’s innovative TRIFLO heart valve and its ongoing PILATUS clinical trial. Initial results will be presented at the EACTS (European Association for Cardio-Thoracic Surgery) conference from October 9-12, 2024, in Lisbon.
“This funding and leadership change come at a pivotal time for Novostia,” said Alexander Valkenberg, Chairman of the Board. “We are deeply grateful for the support from our investors and partners. We are confident that these developments will advance our mission of improving patient outcomes.”
About Novostia
Founded in 2017 and based in Biopôle, Lausanne, Switzerland, Novostia is a privately held medical device company developing the innovative TRIFLO artificial heart valve, currently in human clinical trials.
